Test the whole journey, including failed and cancelled orders—not merely whether an electronic prescription can be sent. Use synthetic data in test environments and follow approved clinical processes for any live pilot.
What should your workflow map contain?
Assign an owner and status for:
Prescription created → received → clarification needed → eligibility/coverage reviewed → payment requested → patient paid → released for fulfilment → dispatched → delivered → exception resolved → refill due
Include parallel states for clinical hold, patient decline, insurer denial, cancellation, transfer request, replacement and refund. Record timestamp definitions and which system is authoritative.
Manufacturer workflows illustrate why these stages should be separate: NovoCare's provider page describes patient account setup, payment, scheduling and delivery as distinct steps. NovoCare workflow.
What acceptance tests should you run?
This proposed test set should be adapted to the route:
- Correct product, presentation, quantity and receiving pharmacy.
- Prescription requiring clarification, with no silent disappearance.
- Insurance denial or programme ineligibility, without automatic unauthorised conversion to self-pay.
- Patient who does not complete payment.
- Address change before and after dispatch.
- Duplicate prescription and cancellation handling.
- Product unavailable in one strength or destination state.
- Damaged package or suspected temperature excursion.
- Lost shipment, replacement and refund reconciliation.
- Patient request for a different pharmacy.
- Supplier outage and recovery of queued orders.
- Recall exercise tracing affected orders and contacting appropriate teams.
- Missing status events, duplicated events and incorrect patient matching.
- Data export and access removal at termination.
For concentration or device changes, require clinician/pharmacist-approved reconciliation and education. FDA's dosing-error warning supports treating these changes as clinical-safety issues, not routine administrative substitutions. FDA alert.
How large should the pilot be?
A proposed planning cohort of 25–50 patients can be useful for exposing workflow defects, provided clinical leadership approves selection and monitoring. This is not a statistically validated quality or safety sample. Include relevant states, payer routes and operational exceptions; exclude cases whose clinical risk makes an operational pilot inappropriate.
Observe at least one refill workflow before declaring recurring access ready. Retain an approved manual fallback when an integration fails.
Stage 7 exit document: signed test results, staff training records, patient communication templates and an unresolved-defect log.
Answers stay in this session unless you choose to save. No account needed.
Sources cited on this page
- novocare.com · Source 1 ↗https://www.novocare.com/hcp/delivery.html
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded